Ryan Haumschild, PharmD, MS, MBA: Welcome to this AJMC ® [The American Journal of Managed Care ®] program titled, “Generalized Pustular Psoriasis: Provider and Payer Considerations for Care.” I am Dr ...

GPP can be triggered by the initiation and withdrawal of various medications, in particular the withdrawal of corticosteroids, and by infections, stress, and other conditions. 1,5,6,10 Patients with a ...

We last explored the relationship between IL-36 and generalized pustular psoriasis (GPP) and the use of spesolimab (SPEVIGO an IL-36 receptor antagonist) six months prior to its September 2022 FDA ...

Please provide your email address to receive an email when new articles are posted on . Imsidolimab yielded a response rate of 75% at 16 weeks in patients with generalized pustular psoriasis. No ...

You’ve probably heard of psoriasis—the chronic inflammatory condition that can cause itchy, scaly patches on your skin. Less well-known is a rare form of the disease called pustular psoriasis, which ...

Generalized pustular psoriasis (GPP) is a severe form of psoriasis characterized by diffuse pustules and plaques with erythema of the underlying skin. The course of the disease varies, with waxing and ...

INGELHEIM, Germany--(BUSINESS WIRE)--EFFISAYIL ™ 2 met its primary and key secondary endpoint, demonstrating that spesolimab, an anti-interleukin-36 receptor antibody, can prevent flares in ...

Please provide your email address to receive an email when new articles are posted on . The mean annualized flare rate per patient per year was 0.91, with a mean time of 5.9 months between flares.

Pustular psoriasis is characterized by clearly defined, raised pus-filled blisters, that cover large swatches of skin and is sometimes accompanied by fever, chills and severe itching. This form of ...

Psoriasis can affect the fingers, knuckles, nails, palms, and soles. Here’s what this psoriasis looks like and how to relieve symptoms like itch.

BRACKNELL, England--(BUSINESS WIRE)--Boehringer Ingelheim announced today the publication in the New England Journal of Medicine of new data from the pivotal Phase II Effisayil TM 1 trial, which ...

New top-line data from a global Phase 3 clinical trial of patients with generalized pustular psoriasis (GPP) flares show rapid clearance of pustulation, erythema and scaling through four weeks after a ...